Elisa Gómez Torrijos

Prof. Dr. Elisa Gómez Torrijos

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2015 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ETElisa Gómez Torrijos
Elisa Gómez Torrijos
RGR. García-Rodríguez
R. García-Rodríguez
ACA. Castro-Jiménez
A. Castro-Jiménez
JRJ. Rodríguez-Sanchez
J. Rodríguez-Sanchez
YDY. Méndez Díaz
Y. Méndez Díaz
JMJ. Molina-Infante
J. Molina-Infante

9 October 2018 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ETElisa Gómez Torrijos
Elisa Gómez Torrijos
RGRosario Gonzalez-Mendiola
Rosario Gonzalez-Mendiola
MAManuela Alvarado
Manuela Alvarado
RARobledo Avila
Robledo Avila
APAlicia Prieto-Garcia
Alicia Prieto-Garcia
JBJoan Bartra
Joan Bartra
Background: Eosinophilic esophagitis (EoE) was first described in the 1990s, showing an increasing incidence and prevalence since then, being the leading cause of food impaction and the major cause of dysphagia. Probably, in a few years, EoE may no longer be considered a rare disease. Methods: This article discusses new aspects of the pathogenesis, symptoms, diagnosis, and treatment of EoE according to the last published guidelines. Results: The epidemiological studies indicate a multifactorial origin for EoE, where environmental and genetic factors take part. EoE affects both children and adults and it is frequently associated with atopic disease and IgE-mediated food allergies. In patients undergoing oral immunotherapy for desensitization from IgE-mediated food allergy the risk of developing EoE is 2.72%. Barrier dysfunction and T-helper 2 inflammation is considered to be pathogenetically important factors. There are different patterns of clinical presentation varying with age and can be masked by adaptation habits. Besides, symptoms do not usually correlate with histologic disease activity. The diagnostic criteria for EoE has evolved but mainly requires symptoms of esophageal dysfunction with histologic evidence of a peak value of at least 15 eosinophils per high-power field. Endoscopies have to be repeated in order to diagnose, monitor, and treat EoE. Treatment of EoE can be started either by drugs (PPIs and topical corticosteroids) or elimination diets. The multistage step-up elimination diet management approach of EoE is promising. Endoscopic dilation is used for patients with severe dysphagia/food impaction with inadequate response to anti-inflammatory treatment. Conclusions: Research in recent years has contributed to a better understanding of EoE's pathogenesis, genetic background, natural history, allergy workup, standardization in assessment of disease activity, evaluation of minimally invasive diagnostic tools, and new therapeutic approaches. However, several unmet needs are to be solved urgently, as finding a non-invasive disease-monitoring methods and biomarkers for routine practice, the development or new therapies, novel food allergy testing to detect triggering foods, drug, and doses required for initial therapy and safety issues with long-term maintenance therapy, amongst others. Besides, multidisciplinary management units of EoE, involving gastroenterologists, pediatricians, allergists, pathologists, dietitians, and ENT specialists are needed.

18 September 2020 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
FMFrancisco Javier Sola Martínez
Francisco Javier Sola Martínez
RJRuth María Barranco Jiménez
Ruth María Barranco Jiménez
CGCristina Martín García
Cristina Martín García
CSCarlos Senent Sánchez
Carlos Senent Sánchez
CGCarlos Blanco Guerra
Carlos Blanco Guerra
RPRicardo Palacios Peláez
Ricardo Palacios Peláez
Background: In allergology, the intradermal approach is generally used to establish an aetiological diagnosis, with limited experience in specific allergen immunotherapy.Objective: To evaluate the efficacy and safety of immunotherapy with an allergen extract of glutaraldehyde‐polymerized Phleum pratense, administered intradermally, in patients with rhinoconjunctivitis sensitized to grass pollen.Methods: Multicentre, randomized, double‐blind, placebo‐controlled clinical trial in patients from 12 to 65 years of age with rhinitis or rhinoconjunctivitis, with or without asthma, due to grass pollen allergy. Patients were divided into three groups and received a total of six doses in a weekly interval, of either placebo; 0.03 or 0.06 μg of protein per dose of P pratense allergoid. The primary objective was to evaluate the combined symptoms and medication consumption score (CSMS). The secondary objectives were symptoms and medication, tolerance to the conjunctival provocation test, specific IgE and IgG4 antibodies and the safety profile according to the WAO scale.Results: The dose of 0.06 μg of protein proved to be effective versus the placebo by significantly reducing CSMS and increasing tolerance to the allergenic extract in the conjunctival provocation test, after the first pollen season. This group showed a significant reduction in specific IgE after the second pollen season relative to the baseline. There were no variations in IgG4 levels. Only one grade 2 systemic reaction was recorded.Conclusion & Clinical Relevance: Intradermal immunotherapy with P pratense allergoid has been shown to be effective and safe, reducing CSMS, increasing tolerance to the conjunctival provocation test and reducing IgE levels.

1 July 2018 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
ETElisa Gómez Torrijos
Elisa Gómez Torrijos
CRCarmen García Rodriguez
Carmen García Rodriguez
BPBeatriz Veleiro Pérez
Beatriz Veleiro Pérez
BBBorja Bartolomé
Borja Bartolomé
MBMarcos Prado Barragan
Marcos Prado Barragan
RRRosa Garcia Rodriguez
Rosa Garcia Rodriguez

12 July 2020 in Contact Dermatitis
Verified
Journal Article
Open access
PDF file
AJAraceli Castro Jiménez
Araceli Castro Jiménez
NNNuria Navarrete Navarrete
Nuria Navarrete Navarrete
AGAlejandro Raúl Gratacós Gómez
Alejandro Raúl Gratacós Gómez
FLFernando Florido López
Fernando Florido López
RRRosa García Rodríguez
Rosa García Rodríguez
ETElisa Gómez Torrijos
Elisa Gómez Torrijos
Click on the article title to read more.

24 February 2023 in Journal of Allergy and Clinical Immunology: Global
Verified
Journal Article
Open access
AGAlejandro Raúl Gratacós Gómez
Alejandro Raúl Gratacós Gómez
SOSara Feo Ortega
Sara Feo Ortega
ACAlberto Palacios Cañas
Alberto Palacios Cañas
FBFrancisco Feo Brito
Francisco Feo Brito
JRJose Ramón Muñoz Rodriguez
Jose Ramón Muñoz Rodriguez
ETElisa Gómez Torrijos
Elisa Gómez Torrijos
Eosinophilic esophagitis (EoE) is a disease characterized by symptoms of esophageal dysfunction and at least 15 eosinophils/hpf in the esophagus. Other systemic and local causes of esophageal eosinophilia should be excluded. The study objectives were to examine the annual epidemiology of EoE for 14 consecutive years, investigate whether there is a relationship between the count of aeroallergens and the incidence of EoE for 12 years, evaluate whether there are family ties between the patients with EoE, and determine whether there are cases of EoE that are triggered or exacerbated by pollens. We conducted a prospective, descriptive, and analytic study in patients with EoE for 14 years (2007-2020). The study variables were age, sex, relatives with EoE, time of evolution of the symptoms until diagnosis of the disease, and symptoms. We examined incidence and prevalence, annual counts of aeroallergens for 12 years, and number of diagnoses per year (in 2007-2020). We studied patients with active EoE (in April-July) and EoE in remission (in August-March) for 2 consecutive years. Exacerbations were investigated by measuring symptoms using a visual analog scale of 1 to 10. Of the 366 patients with EoE (studied from 2007 to 2020), 83.5% were atopic, with respiratory allergy and 28% had a food allergy. Their mean age was 35 years. The time of evolution of the symptoms was more than 6 years. Only 11% of the patients had a degree of kinship. Of the 366 patients, 87% had dysphagia, 27% had had impactions, and 12.5% had other symptoms of esophageal dysfunction. We found a positive correlation between the incidence of EoE and Platanaceae pollens. We did not detect any case of EoE triggered or exacerbated by pollens. The epidemiology of EoE in southwestern Europe continues to grow. We have corroborated the relevant impact of the environment on genetics. Future studies will clarify the possible relevance of Platanaceae pollens in the increased epidemiology of EoE. The role of grass and Oleaceae pollens in triggering EoE is limited by having a short pollination in time.